

# Lysine 270 in the Third Intracellular Domain of the Oxytocin Receptor is an Important Determinant for $G\alpha_q$ Coupling Specificity

MING YANG, WEI WANG, MIAO ZHONG, ANNE PHILIPPI, OLIVIER LICHTARGE, AND BARBARA M. SANBORN

*Department of Biochemistry and Molecular Biology (M.Y., W.W., M.Z., B.M.S.), University of Texas Medical School Houston, Houston, Texas 77030; and Department of Human Genetics (A.P., O.L.), Baylor College of Medicine, Houston, Texas 77030*

To identify structural elements important to specific  $G\alpha_q$  coupling in the oxytocin receptor (OTR), intracellular domains were exchanged between OTR and  $G\alpha_s$ -coupled vasopressin  $V_2$  receptors ( $V_2R$ s). Substitution of sequence from the second (2i) and third (3i) intracellular domains of  $V_2R$  into comparable positions in OTR markedly reduced ligand affinity and resulted in a loss of  $G\alpha_q$  coupling. Substitution of the 2i domain of OTR into  $V_2R$  decreased ligand affinity and vasopressin-stimulated adenylyl cyclase activity and only slightly increased phosphatidylinositol turnover. In contrast, substitution of the OTR3i domain into  $V_2R$  produced a receptor chimera with high ligand affinity, decreased vasopressin-stimulated adenylyl cyclase activity, and markedly enhanced ligand-stimulated phosphatidylinositol turnover. The C-terminal 36 amino acids, but not the N-terminal 13 amino acids, of the OTR3i domain contained the

determinants critical for enhanced activation of PLC. Mutation of a single lysine in the C-terminal OTR3i sequence to the corresponding  $V_2R$  residue (valine) eliminated the enhanced ability of the  $V_2R$  chimera to stimulate PLC but did not affect maximal adenylyl cyclase stimulation. Furthermore, mutation of this residue (K270) in wild-type OTR completely abolished the ability of the receptor to stimulate phosphatidylinositol turnover, with only a small reduction in ligand affinity. These data demonstrate that OTR K270 is critically important in the stimulation by OTR of phosphatidylinositol turnover and that this determinant can also increase this activity in the  $V_2R$  chimera. Mutation of K270 also adversely affects the ability of OTR to stimulate ERK1/2 phosphorylation. Therefore, this residue plays an important role in the specificity of OTR/ $G\alpha_q$ /PLC coupling. (*Molecular Endocrinology* 16: 814–823, 2002)

**A**CTIVATION OF CELLULAR signaling pathways by many hormones occurs via interaction with members of the G protein- (1) coupled receptor (GPCR) superfamily (1–3). The derived amino acid sequence for the oxytocin receptor (OTR) places it in the class I GPCR family (2, 4). Interaction of OTR with its ligand and with target G proteins is key to oxytocin-stimulated signaling in the myometrial smooth muscle of the uterus. Oxytocin-stimulated GTPase and PLC activities can be attenuated by preincubation of myometrial membrane preparations with an antibody directed against the C terminus of  $G\alpha_{q/11}$  (5). These data, together with results from microinjection experiments (6), indicate that OTR couples functionally to  $G\alpha_q$ . In addition, OTR has been reported to couple to  $G\alpha_i$  (7) and  $G\alpha_h$  (8).

Abbreviations: DMEM, DMEM-High glucose; GPCR, G protein-coupled receptor;  $G\alpha_q$ , members of the  $G\alpha_q$  subfamily; hOTR, human OTR; 2i, 3i, and 4i, second, third, and fourth intracellular domains of GPCRs; KA, K268A mutant of OTR and  $V_2R$ OTR3iC; KV, K270V mutant of OTR and  $V_2R$ OTR3iC; KKAV, K268A-K270V double mutant of OTR and  $V_2R$ OTR3iC; OTR, oxytocin receptor; TM, transmembrane;  $V_2R$ , vasopressin  $V_2$  receptor; V1aR, vasopressin V1a receptor.

Random and site-directed mutagenesis, substitution of putative interaction sites in receptor chimeras, and interference assays have implicated the second (2i), third (3i), and fourth (4i) intracellular domains of GPCRs in mediating the specificity and efficacy of coupling to G proteins (1–3). N- and C-terminal regions of GPCR 3i domains appear particularly important for defining G protein specificity in some GPCRs. However, although there is recognizable sequence homology in a given receptor subgroup, there is often a minimum of conservation of specific residues in these regions between receptor subgroups coupling to the same G proteins. This has led to the suggestion that G protein specificity is determined by short sequences defining amphipathic  $\alpha$ -helices at the transmembrane domain/intracellular loop boundaries that may be important only in the context of the specific GPCR sequence (1).

In comparison with the adrenergic and muscarinic subfamilies, relatively little is known about structure/function relationships relating to G protein coupling specificity in the OTR/vasopressin subfamily. Liu and Wess (9) concluded from studies with receptor chimeras that the 2i domain of the vasopressin V1a receptor (V1aR) contained determinants necessary for coupling

to G $\alpha_q$ /PLC, whereas the 3i domain of the vasopressin V<sub>2</sub> receptor (V<sub>2</sub>R) conferred specificity for coupling to G $\alpha_s$ /adenylyl cyclase. In contrast, Qian *et al.* (10) found that the 3i domain of the OTR, when coexpressed in COSM6 cells with OTR and G $\alpha_q$ , effectively inhibited oxytocin-stimulated phosphatidylinositol turnover. Moreover, all of the intracellular domains of OTR had some influence on G $\alpha_q$ -mediated coupling to PLC in this study, whereas the 3i domain of the G $\alpha_s$ -coupled dopamine 1A receptor did not. These data suggested that all or some of the multiple OTR determinants involved in G protein coupling might contribute to interaction specificity.

We constructed OTR/V<sub>2</sub>R chimeras to probe the relationship of structural elements to specific G protein coupling, as reflected in effector stimulation. We found that transfer of the C-terminal 36 amino acids of 3i domain of OTR into V<sub>2</sub>R produced a receptor with enhanced ability to activate PLC. Importantly, a single amino acid substitution (OTR K270 to V), attenuated the ability of both the V<sub>2</sub>R chimera receptor and wild-type OTR to stimulate PLC. These data indicate that this residue in the 3i domain of OTR plays an important role in defining the specificity of OTR/G $\alpha_q$ /PLC coupling.

## RESULTS

### Substitution of OTR3i Sequence into V<sub>2</sub>R Markedly Enhances Vasopressin-Stimulated Phosphatidylinositol Turnover

The seven-transmembrane helical domain structure, substantiated by crystallographic data for rhodopsin, presumably applies to all class I GPCRs (11, 12). The designation of the membrane/cytoplasm boundary is currently somewhat arbitrary, but regions of helices III, V, and VI are predicted to protrude toward the cytoplasm (3, 12–14). A series of hybrid OTR/V<sub>2</sub>R constructs were generated (Fig. 1A) in which equivalent 2i and 3i domain sequences, as defined by the alignments shown in Fig. 1B, were exchanged. Wild-type receptors and receptor chimeras transiently expressed in COS-M6 cells were examined for expression, ligand affinity, and ability to stimulate ligand-dependent adenylyl cyclase and phosphatidylinositol turnover. All of the receptor chimeras were expressed in amounts comparable to wild-type receptor. None of the receptor constructs exhibited constitutive activity, defined as agonist-independent activity.

OTR exhibited a K<sub>d</sub> of 7.8 ± 4 nM for <sup>3</sup>H-oxytocin binding, whereas OTR chimeras containing the V<sub>2</sub>R 2i and 3i domains displayed lower affinity but were expressed at concentrations similar to those of wild-type OTR (Table 1). Neither OTR nor the OTRV<sub>2</sub>R2i or OTRV<sub>2</sub>R3i chimeras stimulated adenylyl cyclase (Table 1). As previously observed (10), OTR exhibited oxytocin-dependent phosphatidylinositol turnover (Table 1). The OTRV<sub>2</sub>R2i and OTRV<sub>2</sub>R3i receptors

were inactive, even at oxytocin concentrations greater than 500 nM.

In contrast to the OTR chimeras, V<sub>2</sub>R chimeras retained or gained the ability to couple to G proteins. V<sub>2</sub>R and V<sub>2</sub>ROTR3i showed high affinity for <sup>3</sup>H-vasopressin, whereas the V<sub>2</sub>ROTR2i receptor chimera exhibited reduced binding affinity (Table 1). As expected, wild-type V<sub>2</sub>R stimulated cAMP production (Table 1); V<sub>2</sub>ROTR2i retained this ability but with lower efficiency and efficacy. In contrast, the V<sub>2</sub>ROTR3i receptor chimera lost the ability to stimulate adenylyl cyclase (Table 1).

At high density, V<sub>2</sub>R can couple to the G $\alpha_q$  family of G proteins and stimulate PLC activity (15). However, using 0.25 μg of V<sub>2</sub>R plasmid for transfection, vasopressin only increased this activity about 2-fold over basal (data not shown). The V<sub>2</sub>ROTR2i receptor chimera exhibited a small but statistically significant enhanced ability to increase ligand-dependent phosphatidylinositol turnover (Fig. 2A). In marked contrast, the V<sub>2</sub>ROTR3i receptor chimera was considerably more active; 40 nM vasopressin elicited a 5.8-fold stimulation (Fig. 2A). This activity was comparable to the oxytocin-induced stimulation by OTR (~5-fold) under comparable conditions. The effect of vasopressin on V<sub>2</sub>ROTR3i was dose dependent (Fig. 2B), with an EC<sub>50</sub> comparable to that of wild-type V<sub>2</sub>R (Table 1). Hence, substitution of the OTR 3i sequence into V<sub>2</sub>R resulted in a receptor chimera with considerably enhanced capability to couple effectively to G proteins that stimulate PLC. Importantly, this occurred with no loss in ligand affinity.

### The C-Terminal Portion of the OTR 3i Domain Contains Important Determinants for Specific G $\alpha_q$ Coupling

To examine further which regions within the OTR 3i domain are of primary importance for G $\alpha_q$  coupling, receptor chimeras in which only N- or C-terminal portions of the V<sub>2</sub>R 3i domain were replaced with OTR sequence were created (Fig. 1). Because the substituted OTR 3i domain is nine amino acids longer than the comparable V<sub>2</sub>R sequence, V<sub>2</sub>ROTR3iCD, in which nine central amino acids of the OTR sequence (G250–A258) were deleted from the V<sub>2</sub>ROTR3iC chimera, was also constructed. Of these chimeras, only V<sub>2</sub>ROTR3iN showed somewhat reduced affinity compared with V<sub>2</sub>R (Fig. 3A and Table 1).

Unlike the V<sub>2</sub>ROTR3i chimera, both V<sub>2</sub>ROTR3iC and V<sub>2</sub>ROTR3iCD, which contain the N-terminal sequence of V<sub>2</sub>R, efficiently stimulated ligand-dependent cAMP accumulation, similar to wild-type V<sub>2</sub>R (Fig. 3B and Table 1). V<sub>2</sub>ROTR3iN also exhibited some ligand-stimulated adenylyl cyclase, but this did not appear to be concentration dependent (Fig. 3B and data not shown); the basis for this behavior is not understood. Importantly, V<sub>2</sub>ROTR3iC and V<sub>2</sub>ROTR3iCD were both able to mediate stimulation of PLC activity, but V<sub>2</sub>ROTR3iN was no more active than wild-type V<sub>2</sub>R (Fig. 3C and Table 1). Therefore, the gain-of-function



**Table 1.** Properties of OTR, V<sub>2</sub>R, and Receptor Chimeras Expressed in COS-M6 Cells

Receptor Construct	Binding		cAMP		IP3 Formation	
	B <sub>max</sub> (fmol/mg P)	K <sub>d</sub> (nM)	R <sub>max</sub> (pmol/ml/mg P)	EC <sub>50</sub> (nM)	R <sub>max</sub> (cpm/ml/mg P)	EC <sub>50</sub> (nM)
OTR	414 ± 81	7.8 ± 4	nd	nd	2,874 ± 129	11.9 ± 2.5
OTRV <sub>2</sub> R2i	442 (2)	56 (2)	nd	nd	nd	nd
OTRV <sub>2</sub> R3i	409 (2)	83 (2)	nd	nd	nd	nd
OTR-K268A	414 ± 47	11.7 ± 3.7	–	–	2,622 ± 167	14.4 ± 1.9
OTR-K270V	383 ± 51	38.3 ± 9.7 <sup>a</sup>	–	–	nd	nd
OTR-KKAV	410 ± 52	49.5 ± 6.2 <sup>a</sup>	–	–	nd	nd
V <sub>2</sub> R	835 ± 66	2.2 ± 0.4	917 ± 26	0.81 ± 0.16	1,019 ± 20	3.2 ± 1.1
V <sub>2</sub> ROTR2i	797 ± 89	109 ± 26 <sup>a</sup>	390 ± 43 <sup>a</sup>	24.6 ± 5.1 <sup>a</sup>	<1,440	nd
V <sub>2</sub> ROTR3i	802 ± 131	2.5 ± 0.4	nd	nd	3,714 ± 239 <sup>a</sup>	0.61 ± 0.1
V <sub>2</sub> ROTR3iN	855 ± 44	12.4 ± 4 <sup>a</sup>	<400	nd	<700	nd
V <sub>2</sub> ROTR3iC	1,181 ± 114 <sup>a</sup>	3.6 ± 0.3	782 ± 87	1.6 ± 1.2	2,668 ± 111 <sup>a</sup>	6.5 ± 2.7
V <sub>2</sub> ROTR3iCD	1,361 ± 100 <sup>a</sup>	2.9 ± 0.6	879 ± 34	1.8 ± 1.2	2,365 ± 69 <sup>a</sup>	2.0 ± 1.0
V <sub>2</sub> ROTR3iC-K268A	830 ± 82	3.4 ± 0.5	956 ± 149	2.5 ± 1.2	2,468 ± 176 <sup>a</sup>	2.4 ± 0.6
V <sub>2</sub> ROTR3iC-K270V	783 ± 133	7.9 ± 1.9 <sup>a</sup>	928 ± 119	10.6 ± 3.1 <sup>a</sup>	1,174 ± 84	21.3 ± 5.8 <sup>a</sup>
V <sub>2</sub> ROTR3iC-KKAV	738 ± 78	24.5 ± 7.5 <sup>a</sup>	<400	nd	1,092 ± 133	19 ± 2 <sup>a</sup>

Maximal binding (B<sub>max</sub>) and affinity (K<sub>d</sub>) were calculated by Scatchard plot and least squares analysis (mean ± SE, n = 3–7 experiments unless indicated otherwise) and confirmed using the LIGAND program on the pooled data. Receptor expression was approximately 76,000 receptors per cell for OTR and OTR mutants and 150,000 receptors per cell for V<sub>2</sub>R and V<sub>2</sub>R mutants. Maximal ligand-stimulated responses (R<sub>max</sub>) and EC<sub>50</sub> values were determined using agonist values in the range from 0.01 to 500 nM and calculated by a four-parameter logistics curve-fitting program. Data represent mean ± SE; n = 3–7 experiments. When the pooled data were analyzed by the LIGAND program, the same conclusions were reached. Values that were below the limits of detection or did not elicit sufficient response to be analyzed are designated as not determinable (nd). –, Not assayed.

<sup>a</sup> Statistically significant differences from the respective wild-type receptor at P < 0.05.

double mutants) in the V<sub>2</sub>ROTR3iC chimera. In the following discussion, V<sub>2</sub>ROTR3iC-KA denotes the K268A mutant, V<sub>2</sub>ROTR3iC-KV denotes the K270V mutant, and V<sub>2</sub>ROTR3iC-KKAV denotes the (K268A, K270V) double mutant.


V<sub>2</sub>ROTR3iC-KA showed an affinity for [<sup>3</sup>H]-8-AVP similar to V<sub>2</sub>R, whereas the affinity of the comparable K270V chimera was reduced 3-fold and that of the KKAV double-mutant chimera was reduced 10-fold (Fig. 4A and Table 1). Both V<sub>2</sub>ROTR3iC-KA and V<sub>2</sub>ROTR3iC-KV still coupled efficiently to G<sub>α<sub>s</sub></sub> (Fig. 4B and Table 1). V<sub>2</sub>ROTR3iC-KKAV exhibited ligand-dependent adenylyl cyclase stimulation, but, like V<sub>2</sub>ROTR3iN, this did not appear to be concentration dependent (Fig. 4B and data not shown). Notably, V<sub>2</sub>ROTR3iC-KA, like V<sub>2</sub>ROTR3i and V<sub>2</sub>ROTR3iC, demonstrated enhanced ability to stimulate PLC compared with wild type V<sub>2</sub>R (Fig. 4C and Table 1). In marked contrast, the single amino acid mutation K270V, as well as the double mutation KKAV, produced receptors that did not increase phosphatidylinositol turnover more than wild-type V<sub>2</sub>R (Fig. 4C and Table 1). Importantly, this reversal in the V<sub>2</sub>ROTR3iC-KV chimera occurred although the affinity for ligand was only slightly decreased and the maximal ability to activate G<sub>α<sub>s</sub></sub> was unaffected.

#### K270 Is Also Critical for OTR Stimulation of PLC and ERK1/2

To test whether K270 is critical for G<sub>α<sub>q</sub></sub> coupling in the context of the OTR receptor itself, we created com-

parable mutants in OTR. OTR and OTR-K268A showed similar affinity for <sup>3</sup>H-oxytocin, whereas the dissociation constant (K<sub>d</sub>) values for OTR-K270V and the double mutant OTR-KKAV were 5- to 6-fold higher (Fig. 5A and Table 1). As found with the V<sub>2</sub>ROTR3iC-KA chimera, OTR-K268A retained the ability to stimulate phosphatidylinositol production with high efficiency and efficacy. In contrast, OTR-K270V and OTR-KKAV completely lost the ability to stimulate PLC (Fig. 5B). These data are consistent with an important role for K270 in G protein coupling to PLC in the OTR.

OTR has also been reported to stimulate ERK1/2 phosphorylation as a result of an increase in diacylglycerol synthesis and PKC activation resulting from activation of the G<sub>α<sub>q</sub></sub>/PLC signaling pathway (16). Determinants for ERK activation have been reported to lie in the fourth but not the third intracellular domain of the receptor (7). To determine whether the activation of ERK1/2 by the OTR was affected by the K270V mutation, we measured ERK1/2 phosphorylation in COSM6 cells transiently transfected with OTR and mutant receptors. Oxytocin (10 nM) significantly stimulated ERK1/2 phosphorylation when OTR was expressed (basal: 1.0 ± 0.4 P-ERK/ERK; OT, 3.4 ± 0.6, n = 3, P < 0.05) and when OTR-K268A was expressed (basal, 1.6 ± 0.2 P-ERK/ERK; OT, 4.8 ± 0.8, n = 3, P < 0.05). In contrast, OTR-K270V and OTR-KKAV completely lost the ability to stimulate ERK1/2 phosphorylation, even at 1000 nM oxytocin (basal, 1.5 ± 0.3 P-ERK/ERK; OT/OTR-K270V, 1.2 ± 0.08; and basal,



**Fig. 2.** Activation of Phosphatidylinositol Turnover by V<sub>2</sub>ROTR Chimeras

A, V<sub>2</sub>ROTR<sub>2i</sub> and V<sub>2</sub>ROTR<sub>3i</sub> exhibit enhanced vasopressin-stimulated phosphatidylinositol turnover relative to V<sub>2</sub>R. Receptor expression did not vary significantly between groups as determined by ligand binding. Data are expressed as mean  $\pm$  SE of triplicates. Data were analyzed by ANOVA and Duncan's modified range test. Significant differences at  $P < 0.05$  between groups are designated by different *lower-case letters*. B, Dose-dependent stimulation by vasopressin of phosphatidylinositol turnover by the V<sub>2</sub>ROTR<sub>3i</sub> receptor chimera. Data represent the mean of duplicates in one of two experiments.

$1.7 \pm 0.26$  P-ERK/ERK; OT/OTR-KKAV,  $1.8 \pm 0.5$ ,  $n = 3$ ). These data indicate that the same amino acid, K270, in the OTR 3i domain, is important for OTR-mediated PLC and for ERK1/2 activation.


## DISCUSSION

How activated GPCRs couple to G proteins is not well understood. The binding of an activating ligand to a GPCR is thought to trigger alterations in interhelix interactions and in the orientation of transmembrane

regions, in particular regions of TMIII and TMVI facing the cytoplasm. These changes, in turn, affect the orientation of intracellular domains that form the receptor cytoplasmic surface, facilitating interaction of receptor determinants with G protein subunits and triggering G protein activation (2, 12, 14, 17–24). In GPCRs, various components of 2i, 3i, and 4i domains have been implicated as points of contact with G proteins (2, 24, 25). In rhodopsin, the 2i and 4i domains project from the receptor surface and create a platform for interaction with transducin  $\alpha$ - and  $\gamma$ -subunits (12, 21). In the G protein  $\alpha$ -subunit N-terminal regions, the region between  $\alpha 4$  and  $\alpha 5$  helices including the  $\beta 6$  loop, and the extreme C-terminal regions have been predicted or directly shown to interact with GPCRs (2, 24–29). The C-terminal five amino acid residues are considered particularly important for determining coupling specificity; interactions with  $\beta\gamma$ -subunits have also been suggested (2). Therefore, the points of interaction between GPCRs and G proteins are not confined to single locations on these proteins. Accordingly, determinants for specificity of interaction may differ from those required to trigger G protein activation, and there is some promiscuity in coupling specificity. Because there is significant heterogeneity in amino acid sequence between GPCR subclasses, particularly in the regions between the transmembrane segments, different residues or even regions in a given receptor may assume primary importance for forming the critical contact points with specific G proteins.


To determine the factors that influence the activation of G proteins stimulating PLC, we constructed a series of chimeras that interchanged sequences between OTR and V<sub>2</sub>R. Although it has not been tested directly in this study, the most likely G proteins involved are the G $\alpha_q$  subfamily (5, 6). Substitution of OTR sequence into V<sub>2</sub>R demonstrated that the C-terminal 36 amino acids of the OTR 3i domain contained determinants sufficient for enhanced activation of PLC by the receptor chimera. Importantly, the 3i domain chimeras are gain-of-function constructs. Mutation of K270 in either V<sub>2</sub>ROTR<sub>3i</sub>C or wild-type OTR to V, the corresponding V<sub>2</sub>R residue, eliminated the enhanced stimulation of phosphatidylinositol turnover; however, V<sub>2</sub>ROTR<sub>3i</sub>C-KV still stimulated G $\alpha_s$ -coupled adenylyl cyclase activity. These data indicate that K270 contributes significantly to the specificity requirement for G $\alpha_q$  activation by OTR and the V<sub>2</sub>R chimera.

Enhancement of PLC activation in V<sub>2</sub>R by substitution of the OTR 3i or OTR 3i C-terminal 36-amino acid sequence implies that other requirements for G protein coupling are fulfilled by the remaining V<sub>2</sub>R sequence. The proximal portion of the 4i domain of OTR has been implicated in specific coupling to G $\alpha_q$  on the basis of studies with truncated mutants (7). However, these results may not be directly comparable to results obtained when domains are interchanged in the context of the intact receptor. The V<sub>2</sub>R 4i domain has been reported to enhance G $\alpha_s$  coupling activity (30) and




**Fig. 3.** The C-Terminal Region of OTR3i Contains Determinants for Enhanced Stimulation of PLC Activity

A, Binding of <sup>3</sup>H-AVP to V<sub>2</sub>R, V<sub>2</sub>ROTR3iN, V<sub>2</sub>ROTR3iC, and V<sub>2</sub>ROTR3iCD. Data represent single points in one of three experiments. B, Ability of V<sub>2</sub>R, V<sub>2</sub>ROTR3iN, V<sub>2</sub>ROTR3iC, and V<sub>2</sub>ROTR3iCD to stimulate adenylyl cyclase. Data were expressed as the mean ± SE of triplicates from one of three experiments. C, Ability of V<sub>2</sub>R, V<sub>2</sub>ROTR3iN, V<sub>2</sub>ROTR3iC, and V<sub>2</sub>ROTR3iCD to stimulate phosphatidylinositide turnover. Data are expressed as the mean ± SE of triplicates from one of three experiments. In panels B and C, data were analyzed as in Fig. 2A.



**Fig. 4.** The K270V Mutation in the V<sub>2</sub>ROTR3iC Chimera Eliminates the Need for Enhanced Stimulation of PLC Activity

A, Binding of <sup>3</sup>H-AVP to V<sub>2</sub>R, V<sub>2</sub>ROTR3iC-KA, V<sub>2</sub>ROTR3iC-KV, and V<sub>2</sub>ROTR3iC-KKAV. Data represent single points in one of three experiments. B, Ability of V<sub>2</sub>R, V<sub>2</sub>ROTR3iC-KA, V<sub>2</sub>ROTR3iC-KV, and V<sub>2</sub>ROTR3iC-KKAV to stimulate adenylyl cyclase. Data are expressed as the mean ± SE of triplicates from one of three experiments. C, Ability of V<sub>2</sub>R, V<sub>2</sub>ROTR3iC-KA, V<sub>2</sub>ROTR3iC-KV, and V<sub>2</sub>ROTR3iC-KKAV to stimulate phosphatidylinositide turnover. Data are expressed as the mean ± SE of triplicates from one of three experiments. In panels B and C, data were analyzed as in Fig. 2A.



**Fig. 5.** The K270V Mutation Eliminates Stimulation of PLC Activity by OTR

A, Binding of <sup>3</sup>H-oxytocin to OTR, OTR-KA, OTR-KV, and OTR-KKAV receptors. Data represent single points in one of three experiments. B, Ability of OTR, OTR-KA, OTR-KV, and OTR-KKAV to stimulate phosphatidylinositol turnover. Data are expressed as the mean  $\pm$  SE of triplicates from one of three experiments. Data were analyzed as in Fig. 2A.

may function in a general manner in the chimeras studied here.

In adrenergic and muscarinic receptors, amino acids in the proximal and distal 3i domains have been implicated in G protein coupling (2). The six-amino acid motif AAXLS (residues 6.33–6.38, located in the rhodopsin structure at positions within the TMVI  $\alpha$ -helix) distinguished muscarinic receptors coupling primarily to  $G_{\alpha_q}$  from those coupling to  $G_{\alpha_{i/o}}$  (2, 31). This sequence is not conserved in the oxytocin/vasopressin receptor family, where the analogous residues for OTR and V<sub>2</sub>R are essentially equivalent (TV[K/R]MT[F/L]) (Fig. 1).

Many GPCRs coupling to different G proteins contain positively charged residues near the C terminus of

the 3i domain (positions 6.28–6.32) that are predicted to form interactions with the head groups of phospholipids at the membrane interface (14). The exact positions and number of charges vary between receptors and may contribute to receptor-specific properties. In rhodopsin, these charged residues form an extension of the TMVI  $\alpha$ -helix (12). A positively charged receptor surface has been predicted at the G protein interface in the rhodopsin receptor (2, 24). R6.32 is conserved as K or R in many receptors coupling to different G proteins, including OTR (R272) and V<sub>2</sub>R (K268). Therefore, although this residue contributes to interaction with and/or activation of G proteins (2), it is unlikely to confer coupling specificity. Our data show that OTR K268 (K6.28) is not critical for coupling efficiency or specificity. In contrast, OTR K270 (K6.30) is required for effective  $G_{\alpha_q}$  coupling. This residue is located in a region implicated in major conformational changes in rhodopsin upon activation and in multiple interactions with the cytoplasmic end of TMIII in a number of GPCRs (12, 14, 19, 20, 22, 32). In both the OTR and the V<sub>2</sub>ROTR3iC chimera, mutation of K270 to V, alone and in combination with the mutation of K268 to A, resulted in some loss in ligand affinity, consistent with a change in some intrareceptor interactions. The exact function of K270, either in interactions with other residues in OTR or with  $G_{\alpha_q}$ , remains to be determined.

Substitution of the OTR 3i domain markedly enhanced phosphatidylinositol turnover in the V<sub>2</sub>ROTR3i chimera, whereas a related V<sub>2</sub>RV1aR3i chimera did not show this property (9). There are no major differences between V1aR and OTR in the C-terminal sequences of the transmembrane/cytosol transition region that would account for this difference. Substitution of C-terminal 3i sequences of V<sub>2</sub>R that included V6.30 into V1aR did not eliminate the ability of the resulting chimeras to stimulate phosphatidylinositol turnover (30). Therefore, K6.30 is apparently not an absolute requirement for  $G_{\alpha_q}$  activation in the context of the V1aR, where other residues or receptor domains may be more important in determining coupling specificity. Position 6.30 is occupied by a negatively charged residue in muscarinic and adrenergic receptors. Hence, the importance of OTR K270 for coupling to  $G_{\alpha_q}$  may well be context dependent.

There are also differences in  $G_{\alpha_s}$  coupling between OTR/V<sub>2</sub>R and V1aR/V<sub>2</sub>R 3i chimeras. OTRV<sub>2</sub>R3i did not stimulate adenylyl cyclase, whereas V1aRV<sub>2</sub>R3i was active (9, 30). A greater structural perturbation, reflected in decreased ligand affinity, or differences in specific residues exchanged may be responsible for the inactivity of OTRV<sub>2</sub>R3i. Q225 and E231 in the N-terminal region of the V<sub>2</sub>R 3i domain have been implicated in effective  $G_{\alpha_s}$  coupling (30). Consistent with this observation, V<sub>2</sub>ROTR3iC and V<sub>2</sub>ROTR3iCD chimeras, both of which retained V<sub>2</sub>R Q225 and E231, stimulated adenylyl cyclase. Notably, V<sub>2</sub>ROTR3i, in which Q225 but not E231 was present, did not stimulate adenylyl cyclase, suggesting an especially critical role for E231.

The role of the OTR 2i domain in G protein coupling specificity is less clear. Replacement of the OTR 2i domain with V<sub>2</sub>R sequence eliminated the ability of the chimeras to stimulate phosphatidylinositol turnover, consistent with our previous observation that both OTR 2i and 3i peptides interfered with OTR/PLC coupling (10). Unfortunately, because affinity for oxytocin was significantly diminished in these chimeras, it is not possible to distinguish between loss of coupling ability due to absence of specific determinants or to changes in receptor configuration. Similarly, V<sub>2</sub>ROTR2i did not simulate cAMP production as effectively as the V<sub>2</sub>RV1a2i chimera. On the other hand, somewhat enhanced G $\alpha_q$  coupling by the V<sub>2</sub>ROTR2i chimera is consistent with results with V1aR/V<sub>2</sub>R chimeras, where G $\alpha_q$  coupling determinants were found in the V1aR 2i domain (9), and with peptide competition studies examining OTR coupling (10). Consistent with these observations, substitution of L for M at position 3.58 in the 2i domain of V<sub>2</sub>R resulted in enhanced interaction in yeast with a G protein containing C-terminal sequence of G $\alpha_q$  (33).

In summary, this study illustrates important differences between OTR and other members of its subfamily and between OTR and other GPCRs with respect to determinants of G protein coupling specificity. In the context of the intact OTR, K270 plays an important role in coupling to G $\alpha_q$  and activation of PLC. In the context of the V<sub>2</sub>R, the C-terminal 36 amino acids of OTR, together with existing V<sub>2</sub>R sequence, can activate G $\alpha_q$ , and OTR K270 plays a critical role in the specificity of this interaction. Additional studies are needed to explore other interactions between the members of this subfamily and the G proteins they stimulate.

## MATERIALS AND METHODS

### Chemicals and Plasmids

[<sup>3</sup>H]-Myoinositol (22.3 Ci/mmol), [<sup>3</sup>H]-oxytocin (44 Ci/mmol), and [<sup>3</sup>H]-8-AVP (37 Ci/mmol) were obtained from DuPont-NEN Life Science Products (Boston, MA). Human oxytocin, 8-AVP, and 3-isobutyl-1-methylxanthine were obtained from Sigma (St. Louis, MO). The human OTR (hOTR) cDNA clone was obtained from Dr. M. J. Brownstein (National Institutes of Mental Health, Bethesda, MD) and the cDNA clone for G $\alpha_q$  from Dr. M. I. Simon (California Institute of Technology, Pasadena, CA). The human V<sub>2</sub>R cDNA clone was obtained from Dr. M. Birnbaumer (UCLA, Los Angeles, CA) and subcloned into the *Eco*RI and *Ap*I sites of pCR3-Uni (Stratagene, La Jolla, CA) for expression studies. Cell culture reagents and Lipofectamine were obtained from Life Technologies, Inc. (Gaithersburg, MD). cAMP Direct Correlate-EIA kit was purchased from Assay Designs Inc. (Ann Arbor, MI). Advantage-GC cDNA polymerase mix was purchased from CLONTECH Laboratories, Inc. (Palo Alto, CA). The Gene Editor *in vitro* site-directed mutagenesis kit was purchased from Promega Corp., (Madison, WI). The antiphospho-p44/42 MAPK monoclonal antibody was purchased from Cell Signaling (Beverly, MA), and polyclonal anti-p44/42 MAPK was obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz CA).

### Sequence Alignment and Construction of Receptor Chimeras

A global alignment of class I (opsin-related) GPCRs, including the OTR and V<sub>2</sub>R subfamily, was performed using an evolutionary trace analysis algorithm (26, 34). The analysis allowed identification of cognate residues in the various receptors and was also used to make a conservative prediction of the extent of helical regions including and extending from the transmembrane domains. Receptor chimeras containing 2i or 3i sequences from human OTR and V<sub>2</sub>R were constructed using PCR splicing by overlap extension techniques (35). The indicated 2i or 3i domains of OTR or V<sub>2</sub>R were interchanged between comparable regions as defined in the alignment analysis shown in Fig. 2B. Other less extensive substitutions were generated by standard PCR procedures. Amino acid mutagenesis was accomplished using Gene Editor (Promega Corp.). All sequence changes were verified by DNA sequencing.

### Cell Culture and Transfection

COS-M6 cells were grown in DMEM-high glucose (DMEM) containing 8% FCS, 2 mM L-glutamine, 50 U/ml penicillin, and 50  $\mu$ g/ml streptomycin. For transient transfection, COS-M6 cells were plated in six-well plates in 1-ml aliquots at a density of  $1.8 \times 10^5$  cells per well and transfected the following day. After rinsing with DMEM, each well received 750  $\mu$ l of DMEM containing plasmid DNA mixed with 6  $\mu$ l Lipofectamine. For ligand binding and cAMP studies, 1  $\mu$ g receptor plasmid was transfected. For phosphatidylinositol turnover, 1  $\mu$ g receptor and 0.05  $\mu$ g G $\alpha_q$  plasmid DNA (OTR and OTR chimeras) or 0.25  $\mu$ g receptor and 0.02  $\mu$ g G $\alpha_q$  plasmid DNA (V<sub>2</sub>R and V<sub>2</sub>R chimeras) were transfected. After 5 h at 37 C, the cells were returned to growth medium, and the medium was changed again 24 h after transfection. Transfection efficiency was estimated by  $\beta$ -galactosidase activity in cotransfection experiments. Protein content on the day of assay ranged between 250 and 330  $\mu$ g/well. Values in the cAMP and phosphatidylinositol turnover assays in the absence of ligand and in untransfected cells were similar.

### Ligand Binding Assay

Two days after transfection, the cells were washed twice with cold HBSS without Ca<sup>2+</sup> or Mg<sup>2+</sup>. Each well received 0.75 ml Ca<sup>2+</sup>-free HBSS containing 5 mM MgCl<sub>2</sub>, 0.1% BSA, and different concentrations of <sup>3</sup>H-labeled ligand as indicated in the absence (total binding) or presence (nonspecific binding) of 20  $\mu$ M unlabeled ligand for 2.5 h at room temperature as described previously (36). The reaction was terminated by aspirating the medium, and the cells were washed with cold HBSS containing 0.1% BSA. Cells were lysed with 0.7 ml 1 N NaOH, and the lysate was neutralized with 0.7 ml 1 M HCl. One milliliter of the neutralized lysate was counted in ScintiSafe Econo 1 (Fisher, Fairlawn, NJ). Specific binding was defined as the difference between total and nonspecific binding.

### cAMP Assay

Two days after transfection, cells were washed twice with HBSS and preincubated in HBSS containing 20 mM HEPES and 1 mM 3-isobutyl-1-methylxanthine for 15 min at 37 C. Cells were stimulated with increasing concentrations of ligand as indicated for 1 h at 37 C. The reaction was terminated by aspiration of the medium and addition of 0.5 ml 0.1 N HCl. cAMP was measured in the cell lysates by immunoassay after acetylation as recommended by the kit manufacturer.

### Phosphatidylinositide Turnover

COS-M6 cells were labeled 24 h after transfection with 0.4  $\mu$ M <sup>3</sup>H-myo-inositol in DMEM with 2% FBS for 15–18 h at 37 C. After labeling, cells were preincubated for 30 min in Dulbecco's PBS supplemented with 10 mM glucose, 1.2 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, and 10 mM LiCl, pH 7.4, and then stimulated for 30 min with increasing concentrations of agonist as indicated. <sup>3</sup>H-Inositol phosphates were isolated and counted in a modification of a previously described procedure (37). Briefly, after the stimulation, the cells were lysed in 1 ml of cold 20 mM formic acid, scraped, and centrifuged. The supernatant was neutralized with 370  $\mu$ l 150 mM NH<sub>4</sub>OH. The extract was applied to a 1-ml AG 1-X8 column, washed with 4 ml of distilled water, and then 4 ml 5 mM sodium borate/60 mM sodium formate. IP3 was eluted with 4 ml of 1 M ammonium formate in 0.1 N formic acid, and 1 ml of sample was counted in Scintisafe.

### ERK1/2 Phosphorylation

Two days after transfection, cells were washed twice with HBSS and stimulated in glucose- and phenol red-free DMEM with oxytocin for 5 min. pERK1/2 and the total amount of ERK1/2 were detected with anti-phospho-p44/42 MAPK and anti-p44/42 MAPK antibody, respectively, in Western blots. Immunoblots were analyzed with a Bio-Rad imaging system (Bio-Rad Laboratories, Inc., Hercules, CA).

### Data Analysis

Affinity and maximal binding were determined by Scatchard plot and least squares analysis and were verified by analysis of the pooled data using the LIGAND program (P. J. Munson, National Institute of Child Health and Human Development, Bethesda, MD). Enzymatic assay concentration dependence was analyzed by a four-parameter logistics curve fitting program (M. L. Jaffe, Silver Spring, MD) and was verified by analysis of the pooled data using the LIGAND program. Where noted, data were analyzed by ANOVA and Duncan's modified range test.

### Acknowledgments

The authors wish to thank Dr. M. Birnbaumer for the V<sub>2</sub>R cDNA.

Received July 9, 2001. Accepted December 6, 2001.

Address all correspondence and requests for reprints to: Dr. Barbara Sanborn, Department of Biochemistry and Molecular Biology, University of Texas Medical School, P.O. Box 20708, Houston, Texas 77225. E-mail: Barbara.M.Sanborn@uth.tmc.edu.

This work was supported in part by NIH Grant HD-09618, R. A. Welch Foundation Grant AU-1373, and NIH Grant T32-07324.

\* Drs. Yang and Wang are equal coauthors.

### REFERENCES

- Hedin KE, Duerson K, Clapham DE 1993 Specificity of receptor-G protein interactions: search for the structure behind the signal. *Cell Signal* 5:505–518
- Wess J 1998 Molecular basis of receptor/G-protein-coupling selectivity. *Pharmacol Ther* 80:231–264
- Schoneberg T, Schultz G, Gudermann T 1999 Structural basis of G protein-coupled receptor function. *Mol Cell Endocrinol* 151:181–193
- Kimura T, Tanizawa O, Mori K, Brownstein MJ 1992 Structure and expression of a human oxytocin receptor. *Nature* 356:526–529
- Ku CY, Qian A, Wen Y, Anwer K, Sanborn BM 1995 Oxytocin stimulates myometrial GTPase and phospholipase C activities via coupling to G $\alpha_{q/11}$ . *Endocrinology* 136:1509–1515
- Arnaudeau S, Lepretre N, Mironneau J 1994 Oxytocin mobilizes calcium from a unique heparin-sensitive and thapsigargin-sensitive store in single myometrial cells from pregnant rats. *Pflugers Arch* 428:51–59
- Hoare S, Copland JA, Strakova Z, Ives K, Jeng YJ, Hellmich MR, Soloff MS 1999 The proximal portion of the COOH terminus of the oxytocin receptor is required for coupling to G $\alpha_q$ , but not G $\alpha_i$ . Independent mechanisms for elevating intracellular calcium concentrations from intracellular stores. *J Biol Chem* 274:28682–28689
- Baek KJ, Kwon NS, Lee HS, Kim MS, Muralidhar P 1996 Oxytocin receptor couples to the 80 kDa G $\alpha_q$  family protein in human myometrium. *Biochem J* 315:739–744
- Liu J, Wess J 1996 Different single receptor domains determine the distinct G protein coupling profiles of members of the vasopressin receptor family. *J Biol Chem* 271:8772–8778
- Qian A, Wang W, Sanborn BM 1998 Evidence for the involvement of several intracellular domains in the coupling of oxytocin receptor to G $\alpha_{q/11}$ . *Cell Signal* 10:101–105
- Unger VM, Hargrave PS, Baldwin JM, Schertler GF 1997 Arrangement of rhodopsin transmembrane  $\alpha$ -helices. *Nature (Lond)* 389:203–206
- Palczewski K, Kumasaka T, Hori T, Behnke AC, Motoshima H, Fox AB, Trong LI, Teller CD, Okada T, Stenkamp ER, Yamamoto M, Miyano M 2000 Crystal structure of rhodopsin: a G protein-coupled receptor. *Science* 289:739–745
- Baldwin JM, Gebhard FX, Schertler and Vinzenz M Unger 1997 An  $\alpha$ -carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. *J Mol Biol* 272:144–164
- Ballesteros JA, Shi L, Javitch JA 2001 Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. *Mol Pharmacol* 60:1–19
- Zhu X, Gilbert S, Birnbaumer M, Birnbaumer L 1994 Dual signaling potential is common among Gs-coupled receptors and dependent on receptor density. *Mol Pharmacol* 46:460–469
- Strakova Z, Copland JA, Lolait SJ, Soloff MS 1998 ERK2 mediates oxytocin-stimulated PGE<sub>2</sub> synthesis. *Am J Physiol* 274:E634–E641
- Farrens DL, Altenbach C, Yang K, Hubbel WL, Khorana HG 1996 Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. *Science* 274:768–770
- Sheikh SP, Zvyaga TA, Lichtarge O, Sakmar TP, Bourne HR 1996 Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F. *Nature* 383:347–350
- Dunham TD, Farrens DL 1999 Conformational change in rhodopsin. Movement of helix F detected by site-specific chemical labeling and fluorescence spectroscopy. *J Biol Chem* 274:1683–1690
- Fanelli F, Barbier P, Zanchetta D, Benedetti PGD, Chini B 1999 Activation mechanism of human oxytocin receptor: a combined study of experimental and computer-simulated mutagenesis. *Mol Pharmacol* 56:214–225
- Bourne HR, Meng EC 2000 Structure. Rhodopsin sees the light. *Science* 289:733–734

22. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen S, Shi L, Gether U, Javitch JA 2001 Activation of the  $\beta_2$  adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. *J Biol Chem* 276:29171–29177
23. Loewen MC, Klein-Seetharaman J, Getmanova EV, Reeves PJ, Schwalbe H, Khorana HG 2001 Solution 19F nuclear Overhauser effects in structural studies of the cytoplasmic domain of mammalian rhodopsin. *Proc Natl Acad Sci USA* 98:4888–4892
24. Hamm HE 2001 How activated receptors couple to G proteins. *Proc Natl Acad Sci USA* 98:4819–4821
25. Onrust R, Herzmark P, Chi P, Garcia PD, Lichtarge O, Kingsley C, Bourne HR 1997 Receptor and  $\beta$   $\gamma$  binding sites in the  $\alpha$  subunit of the retinal G protein transducin. *Science* 275:381–384
26. Lichtarge O, Bourne HR, Cohen FE 1996 An evolutionary trace method defines binding surfaces common to protein families. *J Mol Biol* 257:342–358
27. Oliveira L, Palva ACM, Vriend G 1999 A low resolution model for the interaction of G proteins with G protein-coupled receptors. *Protein Eng* 12:1087–1095
28. Blahos J, Fischer T, Brabet I, Stauffer D, Rovelli G, Bocckaert J, Pin JP 2001 A novel site on the G $\alpha$ -protein that recognizes heptahelical receptors. *J Biol Chem* 276:3262–3269
29. Itoh Y, Cai K, Khorana HG 2001 Mapping of contact sites in complex formation between light-activated rhodopsin and transducin by covalent crosslinking: use of a chemically preactivated reagent. *Proc Natl Acad Sci USA* 98:4883–4887
30. Erlenbach I, Wess J 1998 Molecular basis of V2 vasopressin receptor/G<sub>s</sub> coupling selectivity. *J Biol Chem* 273:26549–26558
31. Hill-Eubank D, Burstein ES, Spaulding TA, Brauner-Osborne H, Brann MR 1996 Structure of G protein-coupling domain of a muscarinic receptor predicted by random saturation mutagenesis. *J Biol Chem* 271:3058–3065
32. Greasley PJ, Fanelli F, Scheer A, Abuin L, Nenninger Tsato M, De Benedetti PG, Cotecchia S 2001 Mutational and computational analysis of the  $\alpha_1b$ -adrenergic receptor; involvement of basic and hydrophobic residues in receptor activation and G protein coupling. *J Biol Chem* 276:46485–46494
33. Erlenbach I, Kostenis E, Schmidt C, Serradeil-Le Gal C, Raufaste D, Dumont ME, Pausch MH, Wess J 2001 Single amino acid substitutions and deletions that alter the G protein coupling properties of V2 vasopressin receptor identified in yeast by receptor random mutagenesis. *J Biol Chem* 276:29382–29392
34. Sowa ME, He W, Slep KC, Kercher MA, Lichtarge O, Wensel TG 2001 Prediction and confirmation of a site critical for effector regulation of RGS domain activity. *Nat Struct Biol* 8:234–237
35. Horton RM 1993 *In vitro* recombination and mutagenesis of DNA. In: White BA, ed. *Methods in molecular biology, PCR protocols*. Totowa, NJ: Humana Press; 251–261
36. Monga M, Ku CY, Dodge K, Sanborn BM 1996 Oxytocin-stimulated responses in a pregnant human immortalized myometrial cell line. *Biol Reprod* 55:427–432
37. Anwer K, Hovington JA, Sanborn BM 1989 Antagonism of contractants and relaxants at the level of intracellular calcium and phosphoinositide turnover in the rat uterus. *Endocrinology* 124:2995–3002

